This third and final webinar in ASLAN’s A⁴ webinar series, “Dialogues with International Thought Leaders in Dermatology” will feature a presentation by Key Opinion Leader (KOL), Peter A Lio, MD, Clinical Assistant Professor at Northwestern University, who will share examples of patient journeys in atopic dermatitis (AD) and highlight the unmet medical needs, patient co-morbidities and limitations of the current treatment landscape.

Dr Carl Firth, Chief Executive Officer at ASLAN, will share new insights from recent market research in AD and provide an overview of eblasakimab (ASLAN004) – a novel, first-in-class monoclonal antibody in phase 2b clinical development for the treatment of moderate-to-severe AD. Eblasakimab targets the IL-13 receptor α1 subunit (IL-13Rα1), one of the components of the Type 2 receptor. By blocking the Type 2 receptor, eblasakimab prevents signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13) – the key drivers of inflammation and itch in AD. The unique mechanism of action has the potential to deliver a differentiated safety and efficacy profile, as well as an improved dosing regimen.

A fireside chat will follow Dr Lio’s presentation which will focus on how new entrants may be positioned alongside existing therapies to address the unmet needs of AD patients.

A live question and answer session will follow the formal presentations.